Development of anti-CXCR2 monoclonal antibodies for tumour therapy [ 2008 - 2009 ]

Research Grant

Researchers: Prof Charles Mackay (Principal investigator) ,  Peter Whitfeld ,  Prof Fabienne Mackay

Brief description New therapies to treat cancers and inflammatory diseases are urgently required. Our aim is to develop a new treatment for cancer and inflammation, by blocking the chemokine receptor CXCR2 which is central to angiogenesis (blood vessel growth) and inflammation. We have produced a highly effective monoclonal antibody (mAb) inhibitor of CXCR2, that is suitable for preclinical and clinical development. The project aims to examine the efficacy of this mAb in mouse tumour models and inflammation.

Funding Amount $AUD 174,867.20

Funding Scheme NHMRC Development Grants

Notes Development Grant